NCT05768529View on ClinicalTrials.gov

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2026

Conditions
Relapsed or Refractory Non-Hodgkin's Lymphoma
Interventions
DRUG

U16

A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.

Trial Locations (2)

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

410013

NOT_YET_RECRUITING

The Third Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY